RG 7697

Drug Profile

RG 7697

Alternative Names: MAR-709; NNC0090-2746; RG7697; RO6811135

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Marcadia Biotech
  • Developer Roche
  • Class Antihyperglycaemics; Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 09 Jun 2017 Adverse events, pharmacodynamics and pharmacokinetics data from a phase I trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 09 Jun 2017 Adverse events, pharmacodynamics and pharmacokinetics data from a phase I trial in Healthy subjects presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 09 Jun 2017 Adverse events and efficacy data from a phase II trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top